Gemini Therapeutics (GMTX) Competitors $64.50 +1.55 (+2.46%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends GMTX vs. QGEN, ITCI, ROIV, ASND, RVMD, LNTH, NUVL, BPMC, ELAN, and LEGNShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Nuvalent (NUVL), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Nuvalent Blueprint Medicines Elanco Animal Health Legend Biotech Qiagen (NYSE:QGEN) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation. Do analysts recommend QGEN or GMTX? Qiagen currently has a consensus price target of $51.88, suggesting a potential upside of 16.13%. Given Qiagen's stronger consensus rating and higher possible upside, research analysts clearly believe Qiagen is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to QGEN or GMTX? In the previous week, Qiagen had 5 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Qiagen and 0 mentions for Gemini Therapeutics. Qiagen's average media sentiment score of 0.47 beat Gemini Therapeutics' score of 0.00 indicating that Qiagen is being referred to more favorably in the media. Company Overall Sentiment Qiagen Neutral Gemini Therapeutics Neutral Which has stronger valuation & earnings, QGEN or GMTX? Qiagen has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.97B5.18$341.30M$0.39114.54Gemini TherapeuticsN/AN/A-$71.87M-$1.00-64.50 Is QGEN or GMTX more profitable? Qiagen has a net margin of 4.73% compared to Gemini Therapeutics' net margin of 0.00%. Qiagen's return on equity of 13.43% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.73% 13.43% 8.10% Gemini Therapeutics N/A -38.78%-35.88% Which has more risk and volatility, QGEN or GMTX? Qiagen has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Do institutionals & insiders have more ownership in QGEN or GMTX? 70.0% of Qiagen shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community prefer QGEN or GMTX? Qiagen received 230 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. However, 63.33% of users gave Gemini Therapeutics an outperform vote while only 60.88% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes24960.88% Underperform Votes16039.12% Gemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% SummaryQiagen beats Gemini Therapeutics on 14 of the 17 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.79B$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-64.5010.4289.5817.17Price / SalesN/A195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book22.325.094.774.78Net Income-$71.87M$151.83M$120.15M$225.60M7 Day Performance-0.60%-2.13%-1.92%-1.23%1 Month Performance3.12%-3.10%11.47%3.36%1 Year Performance13.16%11.54%30.54%16.60% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$64.50+2.5%N/A+10.4%$2.79BN/A-64.5030High Trading VolumeQGENQiagen3.512 of 5 stars$45.40flat$51.15+12.7%+3.1%$10.36B$1.97B117.035,967ITCIIntra-Cellular Therapies4.0477 of 5 stars$84.74+2.1%$97.23+14.7%+27.8%$8.98B$612.78M-95.91560ROIVRoivant Sciences3.0007 of 5 stars$12.05+1.8%$17.93+48.8%+16.2%$8.77B$129.13M2.10860Insider TradeASNDAscendis Pharma A/S3.1363 of 5 stars$135.89+4.6%$191.77+41.1%+12.6%$8.24B$327.43M-16.52640RVMDRevolution Medicines4.5486 of 5 stars$44.80-0.5%$63.67+42.1%+71.5%$7.54B$11.58M-12.54443Insider TradeLNTHLantheus4.3807 of 5 stars$94.48+1.6%$130.00+37.6%+53.4%$6.57B$1.50B15.42834Analyst ForecastNUVLNuvalent2.1944 of 5 stars$86.95+0.1%$112.60+29.5%+16.9%$6.18BN/A-25.0340Insider TradeNews CoveragePositive NewsBPMCBlueprint Medicines2.5701 of 5 stars$95.20+2.2%$122.11+28.3%+7.2%$6.05B$434.42M-45.28640Insider TradeELANElanco Animal Health3.7792 of 5 stars$12.18+0.7%$16.75+37.5%-17.0%$6.02B$4.45B30.259,300LEGNLegend Biotech1.5523 of 5 stars$32.76-6.7%$81.54+148.9%-43.2%$5.98B$520.18M-36.971,800 Related Companies and Tools Related Companies Qiagen Alternatives Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Revolution Medicines Alternatives Lantheus Alternatives Nuvalent Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GMTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
